Stewart and Emily Altman have known Robert Durst for decades, and a prosecutor wants to call them as witnesses in his trial in the murder of Susan Berman.
NYS Entity Status
NYS Filing Date
JUNE 20, 2014
NYS DOS ID#
NYS Entity Type
DOMESTIC LIMITED LIABILITY COMPANY
2014 - ADVANCED CSF THERAPIES, LLC
Around the Web
- Robert Durst’s Friends Resist Demand to Testify in Murder Trial
By CHARLES V. BAGLI - Wednesday Jun 14, 2017
- Trump’s Tough Talk on North Korea Puts Japan’s Leader in Delicate Spot
By JONATHAN SOBLE - Friday Aug 11, 2017
North Korea’s accelerating military advances — and President Trump’s volatile response — could complicate Japan’s close alliance with the United States.
- Gilead Gets FDA Approval for New Cancer Therapy
Wednesday Oct 18, 2017
Gilead Sciences’ $11 billion bet on Kite Pharma is poised to pay off, with the approval of Kite’s flagship cell-therapy treatment for advanced lymphoma patients.
- Is there a suspect in prostitute deaths? Prosecutor is coy
By FRANK ELTMAN, Associated Press - Saturday Sep 16, 2017
MINEOLA, N.Y. (AP) — For years, the thicket along a beach highway on Long Island held a horrible secret. Hidden from passing drivers were the skeletal remains of 10 people, mostly young women who had worked as prostitutes. Who killed them, and why, is a mystery that has vexed a slew of seasoned homicide detectives.The case took an intriguing turn when a veteran county prosecutor became the first authority to publicly name a suspect in at least one of the deaths: John Bittrolff, a Long Island carpenter who was sentenced to consecutive 25 years-to-life terms in prison this week for beating two prostitutes to death in 1993 and 1994.
- FDA advisers review data on potential 1st US gene therapy
By LINDA A. JOHNSON, AP Medical Writer - Wednesday Jul 12, 2017
Cancer experts who advise government regulators are reviewing what could be the first gene therapy approved in the U.S.The Food and Drug Administration panel is holding a hearing Wednesday to discuss the treatment developed by the University of Pennsylvania and Novartis Corp. The drugmaker is seeking approval to use the one-time treatment for children and young adults with advanced leukemia.
- Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
By Ben Fidler - Tuesday Sep 12, 2017
Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]